Midamid (Enzalutamide)

Enzalutamide, the active ingredient in Midamid, is a nonsteroidal antiandrogen presented as an oral formulation for oral use. It treats metastatic castration‑resistant prostate cancer and castration‑resistant prostate cancer in adult men.

GNH USA supplies Midamid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Enzalutamide is used in the management of advanced prostate cancer that no longer responds to hormonal therapy. - Metastatic castration‑resistant prostate cancer: improves overall survival and delays disease progression. - Castration‑resistant prostate cancer: reduces tumor growth and extends time to symptomatic progression. - Non‑metastatic castration‑resistant prostate cancer: delays metastasis and prolongs disease‑free interval.

Enzalutamide may cause a range of adverse reactions. The most frequently reported events are generally mild to moderate.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Hot flashes: sudden feeling of warmth and sweating. - Diarrhea: loose, watery stools. - Nausea: sensation of queasiness. - Decreased appetite: reduced desire to eat. - Constipation: difficulty passing stools.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring immediate medical attention. - Severe hypertension: markedly elevated blood pressure. - Hepatic injury: signs of liver dysfunction such as jaundice. - Interstitial lung disease: breathing difficulties and cough. - Anaphylaxis: severe allergic reaction with rash, swelling, and airway compromise. - Cardiac arrest: sudden loss of heart function.

Before initiating therapy, clinicians should assess patient-specific risk factors and monitor for known safety concerns. - Blood pressure monitoring: check regularly to detect hypertension. - Liver function assessment: evaluate baseline enzymes and repeat as needed. - Seizure risk evaluation: avoid in patients with a history of seizures. - Hypersensitivity screening: discontinue if allergic reactions occur. - Elderly patients: use caution due to increased susceptibility to adverse effects. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Enzalutamide can interact with several medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce enzalutamide exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase enzalutamide levels. - Antiepileptic drugs that lower seizure threshold (e.g., carbamazepine): may increase seizure risk.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Antihypertensives: enzalutamide can raise blood pressure, necessitating dose adjustments. - CYP2C9 substrates (e.g., phenytoin): may experience altered plasma concentrations.